Edition:
United States

Aeterna Zentaris Inc (AEZS.O)

AEZS.O on Consolidated Issue listed on NASDAQ Capital Market

2.15USD
20 Sep 2017
Change (% chg)

$0.05 (+2.33%)
Prev Close
$2.10
Open
$2.15
Day's High
$2.17
Day's Low
$2.10
Volume
62,143
Avg. Vol
2,047,979
52-wk High
$5.59
52-wk Low
$0.78

Chart for

About

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The... (more)

Overall

Beta: 1.12
Market Cap(Mil.): $34.17
Shares Outstanding(Mil.): 16.21
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 80.38 16.25
EPS (TTM): -- -- --
ROI: -- 2.96 14.87
ROE: -- 4.74 13.89

BRIEF-Altitude Resources says Kuro Coal to acquire 100 pct interest in Elan coal project

* Altitude resources inc - entered into a share sale deed under which Kuro coal Canada will purchase 100% of Elan coal ltd

Sep 05 2017

BRIEF-Aeterna Zentaris reports Q2 loss per share $0.18

* Aeterna Zentaris reports second quarter 2017 financial and operating results

Aug 10 2017

BRIEF-Aeterna Zentaris engages advisors and provides update to shareholders

* Aeterna Zentaris engages advisors and provides update to shareholders

Aug 08 2017

BRIEF-David Dodd responds to claim filed by Aeterna Zentaris

* David Dodd, former CEO of Aeterna Zentaris, responds to claim filed by Aeterna Zentaris against him & Philip Theodore​

Aug 04 2017

BRIEF-Aeterna Zentaris files claim against former CEO, former general counsel

* Aeterna Zentaris commences legal action against David Dodd and Philip Theodore

Aug 03 2017

BRIEF-Aeterna Zentaris says ‍strategic review committee will be chaired by Carolyn Egbert, and includes Michael Cardiff​

* Aeterna Zentaris forms strategic review committee and appoints Michael Ward as CEO

Jul 20 2017

BRIEF-NDA for Aeterna Zentaris' Macrilen granted PDUFA date

* NDA for Macrilen for the evaluation of growth hormone deficiency in adults granted December 30, 2017 PDUFA date

Jul 18 2017

BRIEF-Aeterna Zentaris resubmits NDA for Macrilen for the evaluation of growth hormone deficiency in adults

* Aeterna Zentaris resubmits NDA for Macrilen™ for the evaluation of growth hormone deficiency in adults

Jun 30 2017

BRIEF-Aeterna Zentaris says ZoptEC Phase 3 clinical study of Zoptrex did not achieve primary endpoint

* Aeterna Zentaris announces that ZoptEC Phase 3 clinical study of Zoptrex did not achieve its primary endpoint

May 01 2017

BRIEF-Aeterna Zentaris intends to file NDA with respect to Macrilen in Q3

* Aeterna Zentaris intends to file NDA with respect to Macrilen™ in third quarter of 2017 Source text for Eikon: Further company coverage:

Mar 30 2017

Earnings vs. Estimates